Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
May 2023
Litifilimab (BIIB059), a Promising Investigational Drug for Cutaneous Lupus Erythematosus
Expert Opin Investig Drugs 2023;15:1-9 doi 10.1080/13543784.2023.2212154
Cho, et al. discuss the current challenges in the approval of CLE drugs and suggest outcome measures that could streamline the process. They also discuss the pharmacodynamics of litifilimab and the current status of clinical trials.
June 2022
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
Rheumatology (Oxford). 2022;61(6):2413–2423 doi: 10.1093/rheumatology/keab685
Proof-of-concept study for the safety and efficacy of filgotinib (FIL) and lanraplenib (LANRA) in cutaneous lupus (CLE) fails to meet primary endpoint, but select subgroups displayed a numerically greater treatment response to FIL relative to placebo.
March 2022
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials
Lancet Rheumatol. Published online February 3, 2022
Across two pivotal phase 3 trials (TULIP-1 and TULIP-2), anifrolumab treatment improved systemic lupus erythematosus (SLE) disease activity across multiple organ domains, compared with placebo.
February 2022
Real-world Impact of Flaring on Patient-Reported Outcomes and Healthcare Resource Utilisation in Systemic Lupus Erythematosus
Clin Exp Rheumatol. 2021.Epub ahead of print
Data from the real world underscores the need for more effective strategies and treatments to alleviate or prevent flaring in systemic lupus erythematosus (SLE).
Despite data from Hong Kong and Canada showing an association of flaring with reduced health-related quality of life and increased healthcare resourse utilisation and costs, similar international data are limited.
January 2022
Treatment of refractory subacute cutaneous lupus erythematosus with baricitinib
Clin Exp Dermatol. 2021. Epub ahead of print
Phase II data and two individual case reports have shown significant improvement in signs and symptoms of disease in patients with systemic lupus erythematosus (SLE) receiving baricitinib. This case study by Joos et al. reports a further patient with SLE treated successfully with baricitinib.
October 2021
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
N Engl J Med 2020:211–20
Morand et al demonstrate a greater BICLA response at Week 52 for patients treated with anifrolumab versus those treated with placebo.